Researchers at CIRM have synthesized and evaluated new series of original 2-aryloxy/arylamino-5-cyanobenzenesulfonylureas as thromboxane A2 receptor (TP receptor) antagonists.
Based on functional pharmacological test, several compounds were found to be as potent as the 2-arylamino-5-nitrobenzenesulfonylurea reference compound BM-573, supporting the view that the bio-isosteric replacement of the nitro group by a cyano group was tolerated.
TP receptor antagonist activity of the most promising molecules was confirmed in a platelet aggregation assay using the TP receptor agonist U-46619 as a pro-aggregant.
Three compounds were identified as leads for further non-clinical pharmacological and toxicological studies.
Interested in these projects? Drop us an email [firstname.lastname@example.org]. We are looking forward collaborating with you!